-
Neuroprotective efficacy of hypothermia and Inter-alpha Inhibitor Proteins after hypoxic ischemic brain injury in neonatal rats Neurotherapeutics (IF 5.7) Pub Date : 2024-03-06 Xiaodi F. Chen, Yuqi Wu, Boram Kim, Kevin V. Nguyen, Ainuo Chen, Joseph Qiu, Andre R. Santoso, Clemence Disdier, Yow-Pin Lim, Barbara S. Stonestreet
Therapeutic hypothermia is the standard of care for hypoxic-ischemic (HI) encephalopathy. Inter-alpha Inhibitor Proteins (IAIPs) attenuate brain injury after HI in neonatal rats. Human (h) IAIPs (60 mg/kg) or placebo (PL) were given 15 min, 24 and 48 h to postnatal (P) day-7 rats after carotid ligation and 8% oxygen for 90 min with (30 °C) and without (36 °C) exposure to hypothermia 1.5 h after
-
Honokiol hexafluoro confers reversal of neuropathological markers of HIV infection in a murine SCID model Neurotherapeutics (IF 5.7) Pub Date : 2024-02-22 Zhan Zhang, Aaron Scanlan, Rajeth Koneru, Chelsea Richardson Morrell, Monica D. Reece, Emily Edwards, Sebastian Roa, Christina Gavegnano, Heather Bimonte-Nelson, Jack Arbiser, William Tyor
Cognitive impairment remains a persistent challenge in people living with HIV (PWLH) despite antiretroviral therapy (ART) due to ART's inability to eliminate brain HIV. HIV-induced cognitive dysfunction results from immune dysregulation, ongoing neuroinflammation, and the continuous virus presence, collectively contributing to cognitive deficits. Therefore, adjunctive therapies are needed to reduce
-
Ultrahigh frequency transcutaneous electrical nerve stimulation for neuropathic pain alleviation and neuromodulation Neurotherapeutics (IF 5.7) Pub Date : 2024-02-16 Szu-Han Chen, Yu-Wen Lin, Wan-Ling Tseng, Wei-Tso Lin, Sheng-Che Lin, Yuan-Yu Hsueh
A challenging complication in patients with peripheral compressive neuropathy is neuropathic pain. Excessive neuroinflammation at the injury site worsens neuropathic pain and impairs function. Currently, non-invasive modulation techniques like transcutaneous electrical nerve stimulation (TENS) have shown therapeutic promise with positive results. However, the underlying regulatory molecular mechanism
-
Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6/2 mouse model Neurotherapeutics (IF 5.7) Pub Date : 2024-02-16 Talya Shacham, Daniel Offen, Gerardo Z. Lederkremer
There is currently no disease-modifying therapy for Huntington's disease (HD). We recently described a small molecule, MK-28, which restored homeostasis in HD models by specifically activating PKR-like ER kinase (PERK). This activation boosts the unfolded protein response (UPR), thereby reducing endoplasmic reticulum (ER) stress, a central cytotoxic mechanism in HD and other neurodegenerative diseases
-
Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosis Neurotherapeutics (IF 5.7) Pub Date : 2024-02-16 Tiberiu Loredan Stan, Abdolaziz Ronaghi, Sebastian A. Barrientos, Pär Halje, Luciano Censoni, Emilio Garro-Martínez, Azat Nasretdinov, Evgenya Malinina, Stephan Hjorth, Peder Svensson, Susanna Waters, Kristoffer Sahlholm, Per Petersson
Psychosis in Parkinson's disease is a common phenomenon associated with poor outcomes. To clarify the pathophysiology of this condition and the mechanisms of antipsychotic treatments, we have here characterized the neurophysiological brain states induced by clozapine, pimavanserin, and the novel prospective antipsychotic mesdopetam in a rodent model of Parkinson's disease psychosis, based on chronic
-
Repetitive transcranial magnetic stimulation as a treatment for Alzheimer's disease: A randomized placebo-controlled double-blind clinical trial Neurotherapeutics (IF 5.7) Pub Date : 2024-02-14 Zahra Moussavi, Maria Uehara, Grant Rutherford, Brian Lithgow, Colleen Millikin, Xikui Wang, Chandan Saha, Behzad Mansouri, Craig Omelan, Lesley Fellows, Paul B. Fitzgerald, Lisa Koski
-
Focused ultrasound stimulation of infralimbic cortex attenuates reinstatement of methamphetamine-induced conditioned place preference in rats Neurotherapeutics (IF 5.7) Pub Date : 2024-02-13 Chia-Wei Lin, Min-Hsuan Cheng, Ching-Hsiang Fan, Hwei-Hsien Chen, Chih-Kuang Yeh
Methamphetamine (MA) use disorder poses significant challenges to both the affected individuals and society. Current non-drug therapies like transcranial direct-current stimulation and transcranial magnetic stimulation have limitations due to their invasive nature and limited reach to deeper brain areas. Transcranial focused ultrasound (FUS) is gaining attention as a noninvasive option with precise
-
Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy Neurotherapeutics (IF 5.7) Pub Date : 2023-10-26 Sean A. Freeman, Bruno Lemarchant, Tifanie Alberto, Julie Boucher, Olivier Outteryck, Myriam Labalette, Stéphanie Rogeau, Sylvain Dubucquoi, Hélène Zéphir
-
Arterial Glyceryl Trinitrate in Acute Ischemic Stroke After Thrombectomy for Neuroprotection (AGAIN): A Pilot Randomized Controlled Trial Neurotherapeutics (IF 5.7) Pub Date : 2023-10-24 Zhe Cheng, Jie Gao, Yuchuan Ding, Qi Pang, Gary B. Rajah, Xiaokun Geng
-
Magnetic Resonance-Guided Focused Ultrasound Thalamotomy Rebalances Atypical Functional Hierarchy in Patients with Essential Tremor Neurotherapeutics (IF 5.7) Pub Date : 2023-10-16 Jiaji Lin, Xiaopeng Kang, Haoxuan Lu, Dekang Zhang, Xianbing Bian, Jiayou Zhou, Jianxing Hu, Dong Zhang, Jorge Sepulcre, Longsheng Pan, Xin Lou
-
Intravenous Administration of an AAV9 Vector Ubiquitously Expressing C1orf194 Gene Improved CMT-Like Neuropathy in C1orf194-/- Mice Neurotherapeutics (IF 5.7) Pub Date : 2023-10-16 Zongrui Shen, Meiyi Li, Fei He, Cheng Huang, Yingchun Zheng, Zhikui Wang, Shunfei Ma, Li Chen, Zhengshan Liu, Hui Zheng, Fu Xiong
-
Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop Neurotherapeutics (IF 5.7) Pub Date : 2023-10-12 Diane Stephenson, Ramona Belfiore-Oshan, Yashmin Karten, Jessi Keavney, D. Kevin Kwok, Terina Martinez, Joe Montminy, Martijn L. T. M. Müller, Klaus Romero, Sudhir Sivakumaran
-
Wavelet-Based Bracketing, Time–Frequency Beta Burst Detection: New Insights in Parkinson’s Disease Neurotherapeutics (IF 5.7) Pub Date : 2023-10-11 Tanmoy Sil, Ibrahem Hanafi, Hazem Eldebakey, Chiara Palmisano, Jens Volkmann, Muthuraman Muthuraman, Martin M. Reich, Robert Peach
-
D1R-5-HT2AR Uncoupling Reduces Depressive Behaviours via HDAC Signalling Neurotherapeutics (IF 5.7) Pub Date : 2023-10-02 Weifen Li, Tahir Ali, Shengnan Mou, Qichao Gong, Ningning Li, Liangliang Hao, Zhi-Jian Yu, Shupeng Li
-
Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS Neurotherapeutics (IF 5.7) Pub Date : 2023-10-02 Soo Yeon Lee, Hye-Yeon Cho, Jung-Pyo Oh, Jiae Park, Sang-Hun Bae, Haesun Park, Eun Jung Kim, Ji-Hyun Lee
-
Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical. Neurotherapeutics (IF 5.7) Pub Date : 2023-10-04 P K Coyle
-
Letter from the Editor-in-Chief: Neurotherapeutics' Transition to Gold Open Access. Neurotherapeutics (IF 5.7) Pub Date : 2023-10-01 M Maral Mouradian
-
Pharmacotherapy for Traumatic Brain Injury: The Next Generation of Clinical Trials. Neurotherapeutics (IF 5.7) Pub Date : 2023-10-01 Ramon Diaz-Arrastia,Patrick M Kochanek
-
Recombinant Erythropoietin Induces Oligodendrocyte Progenitor Cell Proliferation After Traumatic Brain Injury and Delayed Hypoxemia Neurotherapeutics (IF 5.7) Pub Date : 2023-09-28 Kirill Shumilov, Sophia Xiao, Allen Ni, Marta Celorrio, Stuart H. Friess
-
The Renin Angiotensin System as a Therapeutic Target in Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-09-27 Sonia Villapol, Zachary C. Janatpour, Kwame O. Affram, Aviva J. Symes
-
Optimized Nutrition in Mitochondrial Diseases Correlates with Improved Muscle Fatigue, Strength, and Quality of Life: You Are What You Eat, or Are You? Neurotherapeutics (IF 5.7) Pub Date : 2023-09-28 Russell P Saneto,Amel Karaa
-
Persistent NRG1 Type III Overexpression in Spinal Motor Neurons Has No Therapeutic Effect on ALS-Related Pathology in SOD1G93A Mice Neurotherapeutics (IF 5.7) Pub Date : 2023-09-21 Sara Hernández, Sara Salvany, Anna Casanovas, Lídia Piedrafita, M. Clara Soto-Bernardini, Olga Tarabal, Alba Blasco, Sílvia Gras, Alaó Gatius, Markus H. Schwab, Jordi Calderó, Josep E. Esquerda
-
Optimized Nutrition in Mitochondrial Disease Correlates to Improved Muscle Fatigue, Strength, and Quality of Life Neurotherapeutics (IF 5.7) Pub Date : 2023-09-18 Donna DiVito, Amanda Wellik, Jessica Burfield, James Peterson, Jean Flickinger, Alyssa Tindall, Kimberly Albanowski, Shailee Vishnubhatt, Laura MacMullen, Isaac Martin, Colleen Muraresku, Elizabeth McCormick, Ibrahim George-Sankoh, Shana McCormack, Amy Goldstein, Rebecca Ganetzky, Marc Yudkoff, Rui Xiao, Marni J. Falk, Maria R. Mascarenhas, Zarazuela Zolkipli-Cunningham
-
Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia Neurotherapeutics (IF 5.7) Pub Date : 2023-09-21 Amalia Perna, Kathleen S. Montine, Lon R. White, Thomas J. Montine, Brenna A. Cholerton
-
Frequency-Dependent Reduction of Cybersickness in Virtual Reality by Transcranial Oscillatory Stimulation of the Vestibular Cortex Neurotherapeutics (IF 5.7) Pub Date : 2023-09-18 Alberto Benelli, Francesco Neri, Alessandra Cinti, Patrizio Pasqualetti, Sara M. Romanella, Alessandro Giannotta, David De Monte, Marco Mandalà, Carmelo Smeralda, Domenico Prattichizzo, Emiliano Santarnecchi, Simone Rossi
-
Treating Traumatic Brain Injury with Minocycline Neurotherapeutics (IF 5.7) Pub Date : 2023-09-18 Peter J. Bergold, Rachel Furhang, Siobhán Lawless
-
Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model Neurotherapeutics (IF 5.7) Pub Date : 2023-09-12 Katherine J. Donohue, Bethany Fitzsimmons, Ronald C. Bruntz, Kia H. Markussen, Lyndsay E. A. Young, Harrison A. Clarke, Peyton T. Coburn, Laiken E. Griffith, William Sanders, Jack Klier, Sara N. Burke, Andrew P. Maurer, Berge A. Minassian, Ramon C. Sun, Holly B. Kordasiewisz, Matthew S. Gentry
-
Phosphodiesterase-5 (PDE-5) Inhibitors as Therapy for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-09-11 Priyanka Kalyani, Sara M. Lippa, J. Kent Werner, Franck Amyot, Carol B. Moore, Kimbra Kenney, Ramon Diaz-Arrastia
-
Functional Brain Networks to Evaluate Treatment Responses in Parkinson’s Disease Neurotherapeutics (IF 5.7) Pub Date : 2023-09-08 János A. Barbero, Prashin Unadkat, Yoon Young Choi, David Eidelberg
-
Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy Neurotherapeutics (IF 5.7) Pub Date : 2023-09-06 Eleonora S. D’Ambrosio, Jerry R. Mendell
-
Application of P7C3 Compounds to Investigating and Treating Acute and Chronic Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-31 Preethy S. Sridharan, Emiko Miller, Andrew A. Pieper
-
Neurosteroid Receptor Modulators for Treating Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-31 Todd A. Verdoorn, Tom J. Parry, Graziano Pinna, Jonathan Lifshitz
-
An Understated Comorbidity: The Impact of Homelessness on Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-28 M. Monsour, J.-Y. Lee, C.V. Borlongan
-
Interleukin-1 Receptor Antagonist as Therapy for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-23 Caroline Lindblad, Elham Rostami, Adel Helmy
-
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY) Neurotherapeutics (IF 5.7) Pub Date : 2023-08-23 Clara G. Chisari, Assunta Bianco, Vincenzo Brescia Morra, Massimiliano Calabrese, Fioravante Capone, Paola Cavalla, Carlotta Chiavazza, Cristoforo Comi, Maura Danni, Massimo Filippi, Pietro Iaffaldano, Roberta Lanzillo, Salvatore Lo Fermo, Alessandra Lucisano, Alessandra Lugaresi, Giacomo Lus, Gerolama Alessandra Marfia, Fabiana Marinelli, Massimiliano Mirabella, Lucia Moiola, Chiara Perin, Sabrina
-
Dihydromyricetin Alleviates Ischemic Brain Injury by Antagonizing Pyroptosis in Rats Neurotherapeutics (IF 5.7) Pub Date : 2023-08-21 Huiru Ding, Quancheng Cheng, Xuan Fang, Ziyuan Wang, Jinyu Fang, Huaicun Liu, Junwei Zhang, Chunhua Chen, Weiguang Zhang
-
Fecal Microbiota Transplantation from Aged Mice Render Recipient Mice Resistant to MPTP-Induced Nigrostriatal Degeneration Via a Neurogenesis-Dependent but Inflammation-Independent Manner Neurotherapeutics (IF 5.7) Pub Date : 2023-08-18 Chen-Meng Qiao, Yu Zhou, Wei Quan, Xiao-Yu Ma, Li-Ping Zhao, Yun Shi, Hui Hong, Jian Wu, Gu-Yu Niu, Yu-Nuo Chen, Shan Zhu, Chun Cui, Wei-Jiang Zhao, Yan-Qin Shen
-
The Role of Clinical Assessment in the Era of Biomarkers Neurotherapeutics (IF 5.7) Pub Date : 2023-08-18 Arenn F. Carlos, Keith A. Josephs
-
N-Acetylcysteine and Probenecid Adjuvant Therapy for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-18 Robert S. B. Clark, Philip E. Empey, Patrick M. Kochanek, Michael J. Bell
-
ApoE Mimetic Peptides as Therapy for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-17 Daniel T. Laskowitz, David W. Van Wyck
-
Cyclosporine as Therapy for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-10 Magnus J. Hansson, Eskil Elmér
-
Lessons Learned in Time-Is Neurodegeneration Still Something Unpredictable? Neurotherapeutics (IF 5.7) Pub Date : 2023-08-11 William T Hu
-
Dimethyl Fumarate or Teriflunomide for Relapsing–Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies Neurotherapeutics (IF 5.7) Pub Date : 2023-08-01 Luca Prosperini, Shalom Haggiag, Serena Ruggieri, Carla Tortorella, Claudio Gasperini
-
Olaparib Attenuates Demyelination and Neuroinflammation in an Organotypic Slice Culture Model of Metachromatic Leukodystrophy Neurotherapeutics (IF 5.7) Pub Date : 2023-07-31 Marianna Mekhaeil, Melissa Jane Conroy, Kumlesh Kumar Dev
-
Increasing Rigor of Preclinical Research to Maximize Opportunities for Translation Neurotherapeutics (IF 5.7) Pub Date : 2023-07-31 Hannah L. Radabaugh, Adam R. Ferguson, Helen M. Bramlett, W. Dalton Dietrich
-
A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy Neurotherapeutics (IF 5.7) Pub Date : 2023-07-26 Luca Lo Piccolo, Takanari Umegawachi, Ranchana Yeewa, Saranyapin Potikanond, Wutigri Nimlamool, Virapong Prachayasittikul, Yusuke Gotoh, Hideki Yoshida, Masamitsu Yamaguchi, Salinee Jantrapirom
-
Management Strategies Based on Multi-Modality Neuromonitoring in Severe Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-07-25 Christos Lazaridis, Brandon Foreman
-
Intersectionality in Alzheimer’s Disease: The Role of Female Sex and Black American Race in the Development and Prevalence of Alzheimer’s Disease Neurotherapeutics (IF 5.7) Pub Date : 2023-07-25 Maria B. Misiura, Brittany Butts, Bruno Hammerschlag, Chinkuli Munkombwe, Arianna Bird, Mercedes Fyffe, Asia Hemphill, Vonetta M. Dotson, Whitney Wharton
-
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update Neurotherapeutics (IF 5.7) Pub Date : 2023-07-25 Golnaz Yadollahikhales, Julio C. Rojas
-
Calpain-2 Inhibitors as Therapy for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-07-20 Michel Baudry, Yun Lyna Luo, Xiaoning Bi
-
A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS Neurotherapeutics (IF 5.7) Pub Date : 2023-07-17 Scott D. Newsome, Fan Tian, Thomas Shoemaker, Kathryn C. Fitzgerald, Sandra D. Cassard, Julie Fiol, Sarah Snoops, David S. Cooper, Jennifer S. R. Mammen, Pavan Bhargava, Ellen M. Mowry, Peter A. Calabresi
-
Fingolimod Modulates the Gene Expression of Proteins Engaged in Inflammation and Amyloid-Beta Metabolism and Improves Exploratory and Anxiety-Like Behavior in Obese Mice Neurotherapeutics (IF 5.7) Pub Date : 2023-07-11 P. L. Wencel, K. Blecharz-Klin, A. Piechal, J. Pyrzanowska, D. Mirowska-Guzel, R. P. Strosznajder
-
The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans Neurotherapeutics (IF 5.7) Pub Date : 2023-07-12 Diane Merino, Alexandre O. Gérard, Elise K. Van Obberghen, Alexandre Destere, Michel Lanteri-Minet, Milou-Daniel Drici
Migraine constitutes the world’s second-leading cause of disability. Triptans, as serotonin 5-HT1B/1D receptor agonists, remain the first-line treatment, despite discouraged use in individuals at high cardiovascular risk. Lasmiditan, a selective lipophilic 5-HT1F agonist without vasoconstrictive effects, is an emerging option. We aimed to investigate the safety profile of lasmiditan in the WHO pharmacovigilance
-
A Real-Time Neurophysiologic Stress Test for the Aging Brain: Novel Perioperative and ICU Applications of EEG in Older Surgical Patients Neurotherapeutics (IF 5.7) Pub Date : 2023-07-12 Miles Berger, David Ryu, Melody Reese, Steven McGuigan, Lisbeth A. Evered, Catherine C. Price, David A. Scott, M. Brandon Westover, Roderic Eckenhoff, Laura Bonanni, Aoife Sweeney, Claudio Babiloni
-
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis Neurotherapeutics (IF 5.7) Pub Date : 2023-07-10 Giorgio Lambru, Valeria Caponnetto, Bethany Hill, Susanna Ratti, Simona Sacco, Madeleine Murphy, Jessica Briscoe, Anna P. Andreou
-
Brain-Computer Interface to Deliver Individualized Multisensory Intervention for Neuropathic Pain Neurotherapeutics (IF 5.7) Pub Date : 2023-07-05 Giuseppe Valerio Aurucci, Greta Preatoni, Arianna Damiani, Stanisa Raspopovic
-
Charting the Next Road Map for CSF Biomarkers in Alzheimer’s Disease and Related Dementias Neurotherapeutics (IF 5.7) Pub Date : 2023-06-28 William T. Hu, Ashima Nayyar, Milota Kaluzova
-
Lennox-Gastaut Syndrome: Current Treatments, Novel Therapeutics, and Future Directions Neurotherapeutics (IF 5.7) Pub Date : 2023-06-23 Julie A. Nelson, Kelly G. Knupp
Lennox-Gastaut syndrome is a severe drug-resistant developmental and epileptic encephalopathy with slow spike and wave on EEG (DEE-SSW) composing about 1–2% of epilepsy patients. Seizures in DEE-SSW are caused by a variety of etiologies, and there is a large unmet treatment need as seizures are usually treatment-resistant and individuals are often unable to function independently. The updated definition
-
HMG-CoA Reductase Inhibitors for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-06-23 Kalman Katlowitz, Shankar Gopinath, Jovany Cruz Navarro, Claudia Robertson
-
Oxygen–Glucose Deprived Peripheral Blood Mononuclear Cells Protect Against Ischemic Stroke Neurotherapeutics (IF 5.7) Pub Date : 2023-06-19 Yutaka Otsu, Masahiro Hatakeyama, Takeshi Kanayama, Natsuki Akiyama, Itaru Ninomiya, Kaoru Omae, Taisuke Kato, Osamu Onodera, Masanori Fukushima, Takayoshi Shimohata, Masato Kanazawa